Acute motor neuropathy with quadriparesis following treatment with triple tyrosine kinase inhibitor, nintedanib

Abstract

Idiopathic pulmonary fibrosis (IPF) is a rare progressive interstitial lung disease characterized by declining lung function, worsening dyspnea and poor prognosis with median survival of 3–5 years. IPF predominantly affects people over 60 years, it however has worse prognosis in younger patients with genetic predisposition like short telomere syndrome. Nintedanib, one of two anti-fibrotic therapies approved for IPF treatment has occasional neurological side effects like fatigue, dizziness and headaches. Significant polyneuropathy or motor dysfunction is rarely seen. This case report illustrates a patient who developed quadriparesis following initiation of Nintedanib.

Keywords

• Nintedanib
• Guillain barre
• Interstitial lung disease
• Motor neuropathy
• Idiopathic pulmonary fibrosis